chartexchange

Editas Medicine Announces Third Quarter 2026 Results and Business Updates

GlobeNewswire Inc. | Nov 9, 2026 7:00 AM EST

Company received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia

Read original article